Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition.
Herbal antidiabetic preparations are often used as an add-on therapy in diabetes and such herbal preparations often contains quercetin that can inhibit cytochrome P450 (CYP) 3A4. This enzyme is responsible for metabolizing pioglitazone, a commonly used antidiabetic agent. Hence, it was speculated that quercetin may influence the bioavailability of pioglitazone, which could be particularly crucial, as any increment in its plasma levels may raise safety concerns. Thus, we first established the inhibitory influence of quercetin (2, 10 and 20 mg/kg, p.o.) on CYP3A activity by an in vivo method of estimating levels of midazolam in female rats pretreated with dexamethasone. It was further confirmed in vitro using erythromycin-N-demethylase (EMD) assay. These studies indicated potent inhibition of CYP3A activity by quercetin (10 and 20 mg/kg, in vivo; 1 and 10 microM, in vitro). In another experiment, pioglitazone was administered orally (10 mg/kg) and intravenously (5mg/kg) to quercetin (10 mg/kg) pretreated female rats and its plasma levels were determined at various time points (0.5, 1, 2, 4, 8 and 24 h after oral administration; 0.083, 0.5, 1, 2, 8, 12 and 18 h after i.v. administration) by HPLC. Quercetin pretreatment increased AUC(0-infinity) of pioglitazone after oral administration by 75% and AUC(0-infinity) after intravenous administration by 25% suggesting decreased metabolism, which could be due to inhibition of CYP3A by quercetin. In conclusion, add-on preparations containing quercetin may increase the bioavailability of pioglitazone, and hence should be cautiously used.
Umathe
Sudhir N
SN
Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj (RTM) Nagpur University, Mahatma Jyotiba Fuley Shaikshanik Parisar, Amravati Road, Nagpur 440 033, India. umathesn@hotmail.com
Dixit
Pankaj V
PV
Kumar
Vijendra
V
Bansod
Kuldeep U
KU
Wanjari
Manish M
MM
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001682:Biological Availability; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D007004:Hypoglycemic Agents / Q000097:blood / Q000493:pharmacokinetics*; D008861:Microsomes / Q000378:metabolism; D008874:Midazolam / Q000097:blood / Q000493:pharmacokinetics; D000077205:Pioglitazone; D011794:Quercetin / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D045162:Thiazolidinediones / Q000097:blood / Q000493:pharmacokinetics*
D000975:Antioxidants; D065607:Cytochrome P-450 Enzyme Inhibitors; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D003907:Dexamethasone; D003577:Cytochrome P-450 Enzyme System; D011794:Quercetin; C465260:Cyp3a2 protein, rat; D051544:Cytochrome P-450 CYP3A; D008874:Midazolam; D000077205:Pioglitazone